Last reviewed · How we verify
Mesenchymal stromal cell therapy — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Mesenchymal stromal cell therapy (Mesenchymal stromal cell therapy) — R.P.Herrmann.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mesenchymal stromal cell therapy TARGET | Mesenchymal stromal cell therapy | R.P.Herrmann | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mesenchymal stromal cell therapy CI watch — RSS
- Mesenchymal stromal cell therapy CI watch — Atom
- Mesenchymal stromal cell therapy CI watch — JSON
- Mesenchymal stromal cell therapy alone — RSS
Cite this brief
Drug Landscape (2026). Mesenchymal stromal cell therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/mesenchymal-stromal-cell-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab